Quality of life for cancer chemotherapy patients at PZAGA Mahajanga hospital

Valéry Refeno; Rova M. F. Randrianarisoa; Hasina Andrianarivony Bakohariliva; Harimanana F. F. Rakotondranaivo; Naharisoa G.  Rasamimanana; Florine Rafaramino

doi:10.18203/2320-6012.ijrms20250221

Authors

Valéry Refeno Department of Oncology, Professeur Zafisaona Gabriel University Hospital, Mahajanga, Madagascar
Rova M. F. Randrianarisoa Department of Internal Medicine, Joseph Raseta Befelatanana University Hospital, Antananarivo, Madagascar https://orcid.org/0000-0003-1168-0200
Hasina Andrianarivony Bakohariliva Pediatrics Department, Professeur Zafisaona Gabriel University Hospital, Mahajanga, Madagascar
Harimanana F. F. Rakotondranaivo Department of Oncology, Professeur Zafisaona Gabriel University Hospital, Mahajanga, Madagascar
Naharisoa G. Rasamimanana Emergency and Intensive Care Department, Professeur Zafisaona Gabriel University Hospital, Mahajanga, Madagascar
Florine Rafaramino Faculty of Medicine, Antananarivo, Madagascar

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250221

Keywords:

Cancer, EORTC-QLQ C30, Cancer chemotherapy, Quality of life

Abstract

Background: Cancer chemotherapy is often associated with adverse effects that may be responsible for impaired quality of life. Our aim was to describe the quality of life of patients undergoing cancer chemotherapy at PZAGA Hospital in Mahajanga.

Methods: This was a prospective descriptive study conducted between November 1, 2019 and October 31, 2020, including patients who had received chemotherapy. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) was used.

Results: Forty-six patients agreed to participate in the study. The mean age of the patients was 48.02±14.16 years, with a sex ratio of 0.24. The mean global health status score was 70.83±22.69. For the functional scales, mean scores were 82.90±21.35 (physical functioning), 76.45±33.62 (role functioning), 78.08±19.27 (emotional functioning), 84.06±16.08 (cognitive functioning), and 95.29±10.34 (social functioning). For the symptom scales, mean scores were 21.15±22.15 (fatigue), 11.23±23.32 (nausea and vomiting), 20.29±26.27 (pain), 4.35±13.35 (dyspnea), 19.57±31.09 (insomnia), 15.22±26.95 (appetite loss), 13.04±27.65 (constipation), and 2.17±10.89 (diarrhea). For financial difficulties, the mean score was 42.03±32.53.

Conclusions: The overall quality of life of the patients was good. The disparity in the scores obtained calls for a search for the most vulnerable groups in order to adapt the management.

Metrics

Metrics Loading ...

References

Neugut AI, Prigerson HG. Curative, life-extending, and palliative chemotherapy: new outcomes need new names. Oncologist. 2017;22(8):883-5. DOI: https://doi.org/10.1634/theoncologist.2017-0041

Hassen AM, Taye G, Gizaw M, Hussien FM. Quality of life and associated factors among patients with breast cancer under chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. PLoS One. 2019;14(9):e0222629. DOI: https://doi.org/10.1371/journal.pone.0222629

Lang-Rollin I, Berberich G. Psycho-oncology. Dialogues Clin Neurosci. 2018;20(1):13-22. DOI: https://doi.org/10.31887/DCNS.2018.20.1/ilangrollin

World Health Organization. What quality of life? The WHOQOL Group. World Health Organization Quality of Life assessment. World Health Forum. 1996;17(4):354-6.

Kim K, Yoon H. Health-related quality of life among cancer survivors depending on the occupational status. Int J Environ Res Publ Heal. 2021;18(7):3803. DOI: https://doi.org/10.3390/ijerph18073803

Mokhtari-Hessari P, Montazeri A. Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes. 2020;18(1):338. DOI: https://doi.org/10.1186/s12955-020-01591-x

The Global Cancer Observatory. Madagascar- GLOBOCAN 2020 [fact-sheets]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/450-madagascar-fact-sheets.pdf. Accessed 23 February 2024.

Randriamanovontsoa NE, Razakanaivo M, Andrianandrasana NOTF, Razafiarisoa V, Rafaramino F. Quality of life for patients undergoing chemotherapy for non-metastatic breast cancer. AJOL. 2020;22(3):626-36.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76. DOI: https://doi.org/10.1093/jnci/85.5.365

Abegaz TM, Ayele AA, Gebresillassie BM. Health related quality of life of cancer patients in Ethiopia. J Oncol. 2018;2018:1467595. DOI: https://doi.org/10.1155/2018/1467595

Wondie Y, Hinz A. Quality of life among Ethiopian cancer patients. Supp Care Cancer. 2020;28(11):5469-78. DOI: https://doi.org/10.1007/s00520-020-05398-w

Imran M, Al-Wassia R, Alkhayyat SS, Baig M, Al-Saati BA. Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: a tertiary care center survey in the western region of Saudi Arabia. PLoS One. 2019;14(7):e0219093. DOI: https://doi.org/10.1371/journal.pone.0219093

Perwitasari DA, Purba FD, Candradewi SF, Dania H, Muhammad Irham L, Noor Faridah I, et al. Quality of life of cancer patients during chemotherapy in Indonesia: a comparison of EORTC QLQ-C30 and EQ-5D-5L, based on patients’ characteristics. Int J Clin Pract. 2023;2023:9357299. DOI: https://doi.org/10.1155/2023/9357299

ElMokhallalati Y, Alaloul E, Shatat M, Shneewra T, El Massri S, Shaer O, et al. The symptom burden and quality of life in cancer patients in the Gaza Strip, Palestine: a cross-sectional study. PLoS One. 2022;17(1):e0262512. DOI: https://doi.org/10.1371/journal.pone.0262512

Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol. 2012;51(1):10-6. DOI: https://doi.org/10.3109/0284186X.2011.614636

Zamel ON, Inocian EP, Alshehry AS, Tumala RB, Patalagsa JG, Alsaleh KA. Quality of life among breast and colon cancer patients before and after first-cycle chemotherapy. J Holist Nurs. 2021;39(2):116-25. DOI: https://doi.org/10.1177/0898010120958859

Hinz A, Weis J, Faller H, Brähler E, Härter M, Keller M, et al. Quality of life in cancer patients-a comparison of inpatient, outpatient, and rehabilitation settings. Support Care Cancer. 2018;26(10):3533-41. DOI: https://doi.org/10.1007/s00520-018-4211-4

Elshahat S, Treanor C, Donnelly M. Factors influencing physical activity participation among people living with or beyond cancer: a systematic scoping review. Int J Behav Nutr Phys Act. 2021;18(1):50. DOI: https://doi.org/10.1186/s12966-021-01116-9

Fangel LMV, Panobianco MS, Kebbe LM, Almeida AM, Gozzo TO. Qualify of life and daily activities performance after breast cancer treatment. Acta Paul Enferm. 2013;26(1):93-100. DOI: https://doi.org/10.1590/S0103-21002013000100015

Chen Q, Li S, Wang M, Liu L, Chen G. Health-related quality of life among women breast cancer patients in Eastern China. Biomed Res Int. 2018;2018:1452635. DOI: https://doi.org/10.1155/2018/1452635

Charalambous A, Kouta C. Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int. 2016;2016:3989286. DOI: https://doi.org/10.1155/2016/3989286

Khalladi R, Gargouri I, Zedini C, Ben Saad H. Quality of life of Tunisian patients with lung cancer: descriptive study. Tunis Med. 2019;97(5):626-38.

Finck C, Barradas S, Zenger M, Hinz A. Quality of life in breast cancer patients: associations with optimism and social support. Int J Clin Health Psychol. 2018;18(1):27-34. DOI: https://doi.org/10.1016/j.ijchp.2017.11.002

Országhová Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci. 2021;8:770413. DOI: https://doi.org/10.3389/fmolb.2021.770413

Li CC, Chen ML, Chang TC, Chou HH, Chen MY. Social support buffers the effect of self-esteem on quality of life of early-stage cervical cancer survivors in Taiwan. Eur J Oncol Nurs. 2015;19(5):486-94. DOI: https://doi.org/10.1016/j.ejon.2015.02.008

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260-7. DOI: https://doi.org/10.1093/annonc/mdx100

Reis-Pina P, Sabri E, Birkett NJ, Barbosa A, Lawlor PG. Cancer-related pain: a longitudinal study of time to stable pain control and its clinicodemographic predictors. J Pain Symptom Manag. 2019;58(5):812-23. DOI: https://doi.org/10.1016/j.jpainsymman.2019.06.017

Dzierżanowski T, Mercadante S. Constipation in cancer patients -An update of clinical evidence. Curr Treat Options Oncol. 2022;23(7):936-50. DOI: https://doi.org/10.1007/s11864-022-00976-y

Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, et al. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values. Med J Aust. 2019;210(11):499-506. DOI: https://doi.org/10.5694/mja2.50207

Moten A, Schafer D, Farmer P, Kim J, Ferrari M. Improving cancer care in developing settings. J Glob Health. 2014;4(1):010304. DOI: https://doi.org/10.7189/jogh.04.010304